Differential efficacy of human mesenchymal stem cells based on source of origin

Erin Collins, Fei Gu, Maosong Qi, Ivan Molano, Phillip Ruiz, Lingyun Sun, Gary S. Gilkeson

Research output: Contribution to journalArticle

29 Scopus citations

Abstract

Mesenchymal stem cells (MSCs) are useful in tissue repair but also possess immunomodulatory properties. Murine and uncontrolled human trials suggest efficacy of MSCs in treating lupus. Autologous cells are preferable; however, recent studies suggest that lupus-derived MSCs lack efficacy in treating disease. Thus, the optimum derivation of MSCs for use in lupus is unknown. It is also unknown which invitro assays of MSC function predict invivo efficacy. The objectives for this study were to provide insight into the optimum source of MSCs and to identify invitro assays that predict invivo efficacy. We derived MSCs from four umbilical cords, four healthy bone marrows (BMs), and four lupus BMs. In diseased MRL/lpr mice, MSCs from healthy BM and umbilical cords significantly decreased renal disease, whereas lupus BM MSCs only delayed disease. Current in vitro assays did not differentiate efficacy of the different MSCs. However, differences in MSC efficacy were observed in B cell proliferation assays. Our results suggest that autologous MSCs from lupus patients are not effective in treating disease. Furthermore, standard in vitro assays for MSC licensing are not predictive of in vivo efficacy, whereas inhibiting B cell proliferation appears to differentiate effective MSCs from ineffective MSCs.

Original languageEnglish
Pages (from-to)4381-4390
Number of pages10
JournalJournal of Immunology
Volume193
Issue number9
DOIs
StatePublished - Jan 1 2014

    Fingerprint

ASJC Scopus subject areas

  • Immunology

Cite this